Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK In Pact With India’s Dr Reddy’s; Digs Deeper Into Emerging Generic Drugs Market

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Expanding its reach further into emerging markets for generic drugs, GlaxoSmithKline said it has reached an agreement with Dr. Reddy's Labs to develop and market select products across an extensive number of countries, except India

You may also be interested in...



Slow Traction Clouding GSK-Dr. Reddy’s Expansive Deal?

The landmark 2009 deal between GSK and India’s Dr. Reddy’s to sell branded generic formulations in emerging markets is under serious review. While efforts are underway to redefine a future path and co-operate in a few areas, sources suggest a termination may be among the options being considered.

Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News

GV Prasad, Chairman of the $2.13 billion Indian drug firm Dr. Reddy's Laboratories Ltd. is preparing to take his company from predominantly generics to super generics and untapped innovative niche products. His pet project is lower risk innovation via reverse translation by solving problems with existing molecules.

Dr. Reddy’s Eyes Big Splash In China Market With A Three-fold Sales Jump

After a prolonged wait, Dr. Reddy’s finally finds rhythm in the worlds’ fastest growing market and eyes growth in niche areas.

Related Content

UsernamePublicRestriction

Register

SC071900

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel